S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)

Intuitive Surgical Stock Price, News & Analysis (NASDAQ:ISRG)

$311.75
+0.80 (+0.26%)
(As of 01:21 PM ET)
Compare
Today's Range
$310.01
$316.31
50-Day Range
$258.49
$318.01
52-Week Range
$222.65
$358.07
Volume
527,394 shs
Average Volume
1.75 million shs
Market Capitalization
$109.76 billion
P/E Ratio
73.35
Dividend Yield
N/A
Price Target
$342.71

Intuitive Surgical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
9.7% Upside
$342.71 Price Target
Short Interest
Healthy
0.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.69mentions of Intuitive Surgical in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$15.28 M Sold Last Quarter
Proj. Earnings Growth
13.66%
From $4.54 to $5.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

106th out of 949 stocks

Surgical Appliances & Supplies Industry

6th out of 19 stocks


ISRG stock logo

About Intuitive Surgical Stock (NASDAQ:ISRG)

Intuitive Surgical, Inc. is a leading medical technology company specializing in robotic-assisted surgical systems. Founded in 1995, the company's mission is to improve patient outcomes through the use of innovative technology and minimally invasive surgical techniques. Headquartered in Sunnyvale, California, Intuitive Surgical operates globally, serving healthcare professionals and patients in over 60 countries.

Intuitive Surgical's flagship product is the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. The system consists of robotic arms controlled by the surgeon, along with a high-definition 3D camera and specialized surgical instruments. This advanced technology allows for smaller incisions, reduced scarring, shorter recovery times, and improved clinical outcomes.

The company's target market primarily includes hospitals and surgical centers specializing in urology, gynecology, general, and thoracic surgery. Intuitive Surgical has established itself as a leader in these fields and has a strong customer base, including prestigious medical institutions and renowned surgeons. The company's dedication to innovation and patient care has garnered numerous accolades, including recognition as one of Fortune's "World's Most Admired Companies" in the healthcare industry.

Intuitive Surgical is led by an experienced management team committed to driving the company's growth and maintaining its position as a leader in surgical robotics. Dr. Gary Guthart is the Chief Executive Officer and has been instrumental in guiding the company's strategic direction. Under his leadership, Intuitive Surgical has expanded its product portfolio, entered new markets, and achieved remarkable financial success.

Intuitive Surgical has consistently delivered strong financial performance over the past few years. The company's revenue has experienced steady growth, reaching $6.22 billion in the latest fiscal year. With a strong focus on operational efficiency, Intuitive Surgical has maintained healthy profit margins, enabling it to invest in research and development and expand its market reach.

The company has a solid balance sheet with manageable debt levels. This provides stability and financial flexibility for future investments and acquisitions. Intuitive Surgical's financial performance is notably impressive compared to industry benchmarks, reflecting its strong market position and competitive advantage.

Intuitive Surgical commands a premium compared to its industry peers. The company's price-to-earnings ratio, a commonly used valuation measure, is higher than average due to its strong growth prospects and dominant market position. Investors have recognized the company's innovation and potential for long-term success, contributing to its higher valuation.

Intuitive Surgical has exhibited remarkable stock performance in recent years. The company's share price has experienced significant growth, reflecting investor confidence in its business model and growth potential. Notably, the stock has outperformed broader market indices and many of its industry peers.

Intuitive Surgical operates in the rapidly evolving field of surgical robotics, which is transforming the healthcare landscape. The industry is characterized by intense competition, with major players including Medtronic, Johnson & Johnson, and Stryker Corporation. These companies continually invest in research and development to enhance their robotic surgical systems and expand their market presence.

Regulatory and political factors also play a significant role in the industry. Government agencies, such as the U.S. Food and Drug Administration (FDA), regulate the approval and safety of robotic surgical systems. Changes in regulations or introducing new policies can impact the industry landscape and market access for companies like Intuitive Surgical.

Despite the competitive landscape, Intuitive Surgical maintains a solid competitive advantage. The company's pioneering da Vinci Surgical System has established a dominant position in the market, with a large installed base worldwide. This gives Intuitive Surgical a significant edge in terms of customer loyalty and brand recognition. Additionally, the company's focus on continuous innovation and product development enables it to stay ahead of the competition.

Acquisitions and strategic partnerships offer growth opportunities for Intuitive Surgical. The company has a strong balance sheet enabling it to pursue strategic acquisitions that complement its existing product portfolio or provide access to new markets. Collaborating with other medical technology companies or research institutions can also fuel innovation and open doors to novel surgical solutions.

Like any company operating in the healthcare industry, Intuitive Surgical faces various risks and challenges. One significant risk is the potential for changes in healthcare policies and reimbursement rates. Government policies can directly impact the adoption and utilization of robotic surgical systems, which could affect the demand for Intuitive Surgical's products.

Another challenge is emerging new technologies or surgical techniques that may compete with or disrupt the robotic-assisted surgery market. Technological advancements in artificial intelligence and virtual reality could offer alternative solutions to traditional surgical procedures. Intuitive Surgical must stay at the forefront of innovation and adapt its offerings to remain competitive.

Additionally, the company faces the risk of product recalls or safety concerns. As robotic surgical systems become more complex, ensuring their reliability and patient safety becomes paramount. Intuitive Surgical must continue to invest in quality control measures, regulatory compliance, and ongoing training for surgeons to mitigate these risks.

ISRG Stock Price History

ISRG Stock News Headlines

Intuitive Surgical (NASDAQ:ISRG) Raised to "Buy" at StockNews.com
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Intuitive Surgical: Monopoly Days May Be Over
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Intuitive Surgical (NASDAQ:ISRG) Coverage Initiated at HSBC
Intuitive Surgical initiated with a Buy at HSBC
How to Invest in Intuitive Surgical
See More Headlines
Receive ISRG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intuitive Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/19/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
1/23/2024

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ISRG
CUSIP
46120E60
Employees
12,120
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$342.71
High Stock Price Target
$400.00
Low Stock Price Target
$270.00
Potential Upside/Downside
+10.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
21 Analysts

Profitability

Net Income
$1.32 billion
Pretax Margin
26.83%

Debt

Sales & Book Value

Annual Sales
$6.22 billion
Cash Flow
$4.74 per share
Book Value
$31.45 per share

Miscellaneous

Free Float
348,903,000
Market Cap
$109.48 billion
Optionable
Optionable
Beta
1.31

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Intuitive Surgical was last updated on Thursday, November 16, 2023 at 12:00 AM.

Pros

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

  • The da Vinci Surgical System, developed by Intuitive Surgical, is a revolutionary robotic-assisted surgery system that has been in use for over 23 years and has performed over 10 million surgeries worldwide. This established track record demonstrates the reliability and effectiveness of the system.
  • Intuitive Surgical has a large installed base of 7,779 robotic systems, which generates revenues not only from surgeries but also from equipment, training, and support. This diversified revenue stream provides stability and potential for growth.
  • Despite disruptions caused by the pandemic, Intuitive Surgical is recovering as elective and non-emergency surgeries resume. The lifting of COVID-19 restrictions in China, a key market for the company, is expected to provide a tailwind for future growth.
  • Intuitive Surgical has dominated the robot-assisted surgery market for over two decades, maintaining its position as the leader in the industry. This market dominance gives the company a competitive advantage and strengthens its long-term prospects.
  • The company continues to innovate and expand its digital services, which can enhance the value proposition for customers and potentially drive additional revenue growth.

Cons

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

  • Investing in Intuitive Surgical, Inc. carries risks associated with the healthcare industry, including regulatory challenges, reimbursement uncertainties, and potential changes in healthcare policies that could impact the adoption and utilization of robotic-assisted surgery systems.
  • The stock price of Intuitive Surgical, Inc. should be considered, as it can fluctuate based on market conditions, investor sentiment, and company-specific factors. Investors should carefully evaluate the current stock price and consider their risk tolerance before making investment decisions.
  • Competition in the medical device industry, although currently not a significant threat, could intensify in the future. Other companies may develop competing robotic-assisted surgery systems or alternative technologies that could disrupt Intuitive Surgical's market position.
  • The COVID-19 pandemic has demonstrated the vulnerability of healthcare systems to external shocks. While Intuitive Surgical is recovering from the pandemic, future outbreaks or other unforeseen events could impact the demand for surgical procedures and the company's financial performance.
  • Investors should also consider the financial health and performance of Intuitive Surgical, Inc. This includes analyzing factors such as revenue growth, profitability, debt levels, and cash flow to assess the company's ability to generate sustainable returns for investors.














ISRG Stock Analysis - Frequently Asked Questions

Should I buy or sell Intuitive Surgical stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last twelve months. There are currently 4 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ISRG shares.
View ISRG analyst ratings
or view top-rated stocks.

What is Intuitive Surgical's stock price target for 2024?

21 Wall Street analysts have issued 1-year price objectives for Intuitive Surgical's shares. Their ISRG share price targets range from $270.00 to $400.00. On average, they predict the company's stock price to reach $342.71 in the next year. This suggests a possible upside of 10.2% from the stock's current price.
View analysts price targets for ISRG
or view top-rated stocks among Wall Street analysts.

How have ISRG shares performed in 2023?

Intuitive Surgical's stock was trading at $265.35 at the start of the year. Since then, ISRG stock has increased by 17.2% and is now trading at $311.11.
View the best growth stocks for 2023 here
.

Are investors shorting Intuitive Surgical?

Intuitive Surgical saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,450,000 shares, an increase of 19.0% from the October 31st total of 2,900,000 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is currently 1.8 days.
View Intuitive Surgical's Short Interest
.

When is Intuitive Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 23rd 2024.
View our ISRG earnings forecast
.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) released its earnings results on Thursday, October, 19th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.41 by $0.05. The medical equipment provider earned $1.74 billion during the quarter, compared to the consensus estimate of $1.77 billion. Intuitive Surgical had a trailing twelve-month return on equity of 12.91% and a net margin of 22.14%. The business's revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.90 earnings per share.
Read the conference call transcript
.

When did Intuitive Surgical's stock split?

Intuitive Surgical shares split on the morning of Tuesday, October 5th 2021. The 3-1 split was announced on Thursday, August 5th 2021. The newly created shares were payable to shareholders after the market closes on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What is Gary S. Guthart's approval rating as Intuitive Surgical's CEO?

431 employees have rated Intuitive Surgical Chief Executive Officer Gary S. Guthart on Glassdoor.com. Gary S. Guthart has an approval rating of 99% among the company's employees. This puts Gary S. Guthart in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intuitive Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intuitive Surgical investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Salesforce (CRM), PayPal (PYPL), Walt Disney (DIS), Boeing (BA), Mastercard (MA) and Adobe (ADBE).

Who are Intuitive Surgical's major shareholders?

Intuitive Surgical's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (2.19%), Bank of New York Mellon Corp (1.97%), Morgan Stanley (1.51%), Jennison Associates LLC (1.30%), Baillie Gifford & Co. (1.16%) and Invesco Ltd. (1.07%). Insiders that own company stock include Alan J Levy, Amal M Johnson, Amy L Ladd, Craig H Barratt, Craig H Barratt, Curet Myriam, David J Rosa, David J Rosa, Fredrik Widman, Gary S Guthart, Gary S Guthart, Jamie Samath, Keith R Leonard, Mark J Rubash, Mark J Rubash, Marshall Mohr, Myriam Curet, Reiter Kara Andersen and Robert Desantis.
View institutional ownership trends
.

How do I buy shares of Intuitive Surgical?

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Intuitive Surgical have any subsidiaries?
The following companies are subsidiares of Intuitive Surgical: Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical BV, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, Intuitive Surgical Canada Inc, Intuitive Surgical Deutschland GmbH, Intuitive Surgical Fosun HongKong Co Ltd, Intuitive Surgical Fosun Medical Technology Shanghai Co Ltd, Intuitive Surgical GK, Intuitive Surgical HK Limited, Intuitive Surgical Holdings LLC, Intuitive Surgical India Private Limited, Intuitive Surgical International BV, Intuitive Surgical International Finance LLC, Intuitive Surgical Ireland Limited, Intuitive Surgical Israel Ltd, Intuitive Surgical Korea Limited, Intuitive Surgical Limited, Intuitive Surgical Medical Device Science & Technology Shanghai Co Ltd, Intuitive Surgical Medical Device Taiwan Ltd, Intuitive Surgical Operations Inc, Intuitive Surgical Optics Gmbh, Intuitive Surgical Pte Ltd, Intuitive Surgical S de R L de CV, Intuitive Surgical SAS, Intuitive Surgical SPRL, Intuitive Surgical Sarl, Intuitive Surgical Sarl Taiwan Branch, Intuitive Surgical Service Optics Inc, Intuitive Surgical Spain SL, Intuitive Surgical Turkey Medikal Cihaz Ticaret Limited Serketi, Intuitive Surgical sro, Intuitive Ventures Fund I LLC, NeoGuide Systems, Orpheus Medical, Orpheus Medical Gmbh, Orpheus Medical Inc, Orpheus Medical Ltd, Orpheus Medical USA Inc, and Scholly Micro Optics Gmbh.
Read More
This page (NASDAQ:ISRG) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -